Cargando…
The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719732/ https://www.ncbi.nlm.nih.gov/pubmed/33287853 http://dx.doi.org/10.1186/s13054-020-03406-3 |
| _version_ | 1783619736906498048 |
|---|---|
| author | Frost, Matilde Tejlbo Jimenez-Solem, Espen Ankarfeldt, Mikkel Zöllner Nyeland, Martin Erik Andreasen, Anne Helms Petersen, Tonny Studsgaard |
| author_facet | Frost, Matilde Tejlbo Jimenez-Solem, Espen Ankarfeldt, Mikkel Zöllner Nyeland, Martin Erik Andreasen, Anne Helms Petersen, Tonny Studsgaard |
| author_sort | Frost, Matilde Tejlbo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7719732 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77197322020-12-07 The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study Frost, Matilde Tejlbo Jimenez-Solem, Espen Ankarfeldt, Mikkel Zöllner Nyeland, Martin Erik Andreasen, Anne Helms Petersen, Tonny Studsgaard Crit Care Research Letter BioMed Central 2020-12-07 /pmc/articles/PMC7719732/ /pubmed/33287853 http://dx.doi.org/10.1186/s13054-020-03406-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Research Letter Frost, Matilde Tejlbo Jimenez-Solem, Espen Ankarfeldt, Mikkel Zöllner Nyeland, Martin Erik Andreasen, Anne Helms Petersen, Tonny Studsgaard The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study |
| title | The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study |
| title_full | The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study |
| title_fullStr | The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study |
| title_full_unstemmed | The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study |
| title_short | The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study |
| title_sort | adaptive covid-19 treatment trial-1 (actt-1) in a real-world population: a comparative observational study |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719732/ https://www.ncbi.nlm.nih.gov/pubmed/33287853 http://dx.doi.org/10.1186/s13054-020-03406-3 |
| work_keys_str_mv | AT frostmatildetejlbo theadaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT jimenezsolemespen theadaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT ankarfeldtmikkelzollner theadaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT nyelandmartinerik theadaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT andreasenannehelms theadaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT petersentonnystudsgaard theadaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT frostmatildetejlbo adaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT jimenezsolemespen adaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT ankarfeldtmikkelzollner adaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT nyelandmartinerik adaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT andreasenannehelms adaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy AT petersentonnystudsgaard adaptivecovid19treatmenttrial1actt1inarealworldpopulationacomparativeobservationalstudy |